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and to 50mg in 3% of pts. The reasons for dose reduction were mainly 
rash 54%, diarrhea 19.4%, pruritus 9.7%; rash and diarrhea 6.5%. 
Conclusions: Based on a large number of unselected pts with advanced 
NSCLC in Israel, the safety data obtained from the interim results 
with erlotinib conﬁrm the favorable safety proﬁle of erlotinib previ-
ously observed in clinical trials. To date, the results show erlotinib 
to be generally well tolerated, thus allowing most pts to receive the 
recommended daily dose of 150mg. Efﬁcacy data may be available by 
September 2007.
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Background: The addition of bevacizumab (B) to chemotherapy 
improves survival in patients (pts) with previously untreated metastatic 
NSCLC. The addition of bevacizumab to erlotinib (E) appears promis-
ing in second line therapy of NSCLC. Bevacizumab plus erlotinib 
(B+E) has never been tested in 1st line NSCLC. 
Methods: Eligible pts with previously untreated stage IIIB (pleural 
effusion) or stage IV NSCLC and normal organ function without 
hemoptysis or brain metastasis were treated with B (15mg/kg every 21 
days) plus E (150mg once daily) for 4 cycles (cycle- 21 days) followed 
by B (15mg/kg), carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 
21 days for 4 cycles. Pts who did not progress on initial B+E received 
maintenance therapy with B+E until progression.
Results: We have enrolled 40 pts (of 48 planned) in this ongoing study. 
The characteristics: 25 male, 15 female; median age 70 years; 37 stage 
IV, 3 stage IIIB; 3 never smokers; 26 adenocarcinoma, 10 non-small 
cell lung cancer not otherwise speciﬁed, 3 undifferentiated carcinoma, 
1 adenocarcinoma with BAC; performance status 0 in 16 and 1 in 
24. Twenty three pts have completed 4 cycles of B+E with 5 partial 
responses (22%), 13 stable disease (56%) and 5 progressive disease 
(22%). Sixteen pts have completed bevacizumab plus chemotherapy 
with best responses of 5 partial response (31%), 9 stable disease (56%), 
2 progressive disease (12%). Of the 11 pts treated with maintenance 
B+E, 4 developed progressive disease and have discontinued therapy. 
The median number of cycles received during maintenance therapy 
with B+E was 6 (range 2-15+). Treatment related toxicities: related to 
B+E- grade 3 rash (3 pts), grade 3 fatigue (2 pts), and grade 3 epistaxis 
(1 pt); related to B and chemotherapy- grade 3 neuropathy (2 pts), 
grade 3 hypersensitivity reaction (1 pt), grade 4 neutropenia (2 pts), 
and grade 4 arterial thrombosis (1 pt). Most notably, there have been no 
major bleeding episodes so far. 
Conclusions: 1. The combination of B+E achieved a disease control 
rate of 78% in previously untreated patients with IIIB/IV NSCLC and 
is well tolerated. 2. The initial administration of 4 cycles of B+E does 
not impair the efﬁcacy platinum based doublet chemotherapy with 
bevacizumab.
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Background: The epidermal growth factor receptor (EGFR) is ex-
pressed in many human epithelial malignancies, including NSCLC. The 
response rates to EGFR tyrosine kinase inhibitors (TKIs) in unselected 
NSCLC patients rages from 9-27%. NSCLC cell lines highly sensitive 
to EGFR TKIs express E-cadherin. Patients with high E-cadherin ex-
pression in tumors samples have improved time-to-progression (TTP) 
after treatment with EGFR TKI erlotinib, indicating the signiﬁcant role 
of epithelial-mesenchymal transition (EMT) to predict sensitivity/re-
sistance to EGFR inhibitors. These results suggest that high E-cadherin 
expression would be a clinically relevant biomarker for patient’s selec-
tion to EGFR TKI therapy. The aim of the present study was to investi-
gate the potential association between serum E-cadherin expression and 
clinical activity of geﬁtinib in European NSCLC patients. 
Methods and Results: Serum E-cadherin levels were evaluated by 
ELISA using commercially available kit (R&D Systems). Statistical 
evaluation was performed by Kaplan-Meier analysis and a Cox pro-
portional hazard model. Among 135 consecutive patients treated with 
geﬁtinib (median age, 67 years; 75% males; 83% ever smokers), 123 
were evaluable for response, TTP and overall survival (OS). Forty-four 
(36%) had stable disease (SD) and 15 (13%) had objective response 
(OR). Serum E-cadherin levels ranged from 15 to 203 ng/mL with a 
median value of 30 ng/mL. The whole population was divided into two 
groups based on median E-cadherin levels (< 30 versus ≥ 30 ng/mL). 
Higher serum E-cadherin level was observed in patients with older age 
(P=.003), ECOG PS of 2 versus 0 or 1 (P=.027), and squamous cell 
histology (P=.045).
The response rates were 13% and 11% in patients with low and high 
E-cadherin level, respectively (P=.809); disease control rates were 52% 
and 44% respectively (P=.415). Median TTP and OS were 3.5 and 5.8 
months, and 3 and 7 months, in patients with low and high E-cadherin 
levels (P=.245; P=.434 respectively). 
Conclusions: These results indicate that higher E-cadherin levels are 
associated with age, advanced PS and squamous cell histology. Serum 
E-cadherin does not appear to predict response, TTP, and OS in patients 
with NSCLC after therapy with geﬁtinib. Corresponding E-cadherin 
tissue studies are ongoing.
P3-089 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Gefitinib (G) treatment outcome after progression on erlotinib (E) 
in patients with advanced non-small-cell lung cancer (NSCLC)
Grossi, Francesco; Defferrari, Carlotta; Brianti, Annalisa; Loprevite, 
Maura; Catania, Gianluca; Dal Bello, Maria Giovanna; Pronzato, Paolo 
National Institute for Cancer Research, Genova, Italy
Background: Two case reports describe a response to E after failure of 
G (Garﬁeld DH, J Clin Oncol 2005) or to G after failure of E (Choong 
NW et al, Nat Clin Pract Oncol 2006) in patients (pts) with advanced 
NSCLC. Otherwise, a limited experience in 5 pts suggests that E is not 
